Hospital Infection Therapeutics Market Size to Hit USD 20.8 Bn by 2030

According to Nova one advisor, the global Hospital Infection Therapeutics market size is expected to hit around USD 20.8 billion by 2030 from valued at USD 11.9 billion in 2021 and growing at a CAGR of 4.4% from 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7139

The high prevalence of HAIs, approval & launch of new therapies, and increasing R&D initiatives are some of the major factors driving the market for HAIs therapeutics. 

Hospital acquired infection (HAI), also called nosocomial infection is caused by bacterial, fungal, and viral pathogens while receiving treatment in health care facilities. The most common types of HAIs include urinary tract infection (UTI), pneumonia (e.g. ventilator-associated pneumonia (VAP)), surgical site infection (SSI), and bloodstream infection (BSI). The high prevalence of these HAIs is expected to significantly drive the demand for its therapeutics and fuel market growth in the coming years. According to the report published by the Organisation for Economic Co-operation and Development (OECD) in 2018, annually around 3.8 million people in EU countries acquire a healthcare-associated infection in acute care hospitals. The same source also states that each year around 90,000 people in the EU countries die due to some type of HAIs.

According to the data published by the New York State Department of Health in November 2019, around 160 hospitals in New York reported total cases of around 1,139 colon SSIs out of 19,732 procedures in 2018, a rate of 5.8 infections per 100 procedures. The same source also states that in 2018, around 15,310 cases of Clostridioides difficile infections (CDI) were reported in acute care hospitals located in New York. Such, high prevalence of hospital-acquired infections is anticipated to significantly raise the demand for its treatment therapies and support the HAIs therapeutics market growth over the forecast period.

Furthermore, key players in the market are involved in extensive R&D initiatives for the development and indication expansion of its already approved drugs for HAI treatment. For instance, in February 2018, the FDA approved Allergan plc’s supplemental New Drug Application (sNDA) and expanded the approval of Avycaz (ceftazidime and avibactam) to include the treatment of HABP/VABP and hospital-acquired bacterial pneumonia.

Report Scope of the Hospital Infection Therapeutics Market

 Key Takeaways:

• Antibacterial drugs dominated the drug class segment in 2021, owing to the high adoption of antibiotics as the first line of treatment for hospital-acquired infections (HAIs)
• The surgical site infections (SSIs) segment held the largest market share in 2019 due to the rising number of surgical procedures and subsequent rising cases of SSIs
• The urinary tract infections (UTIs) segment is anticipated to show the fastest growth rate during the forecast period owing to the growing number of UTI cases and rising awareness among people about the disease condition in less-developed countries
• The introduction of novel drugs by key players, for instance, Merck to treat ventilator-associated pneumonia has led to a high growth of the market
• The high prevalence of HAIs in the European countries is the major factor significantly driving the demand for its medications in this region
• Growing awareness levels about various risk factors associated with HAIs in ICU and other emergency care settings is expected to propel market growth in the Asia Pacific region

Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7139

Regional Insights

Europe dominated the market for HAIs therapeutics and accounted for the largest revenue share of 36.4% in 2021 and is expected to dominate the market throughout the study period. This dominance is attributed to the high prevalence of HAIs in European countries and increasing approvals and launch of novel HAI therapeutic drugs in the region. Furthermore, higher accessibility of novel hospital-acquired infection therapeutics in the European countries due to the local presence of major players such as GlaxoSmithKline Plc, F. Hoffmann-La Roche AG., Allergan Plc, and Bayer AG is further expected to support regional growth.

In Asia Pacific, the market for HAIs therapeutics is anticipated to show significant growth during the forecast period. This growth is attributed to the increasing prevalence of chronic diseases in emerging economies such as India and China which has led to increased hospitalizations. For instance, according to the data published by Globocan, in 2018 around 4,285,033 new cases of cancer were diagnosed in China. Thus, the increasing rate of HAIs with increasing hospitalizations is anticipated to foster demand for HAI therapeutic drugs and support regional growth.

Some of the prominent players in the Hospital Infection Therapeutics Market include:

• Merck & Co., Inc.
• Pfizer Inc.
• Bayer AG
• GlaxoSmithKline Plc.
• Daiichi Sankyo Company, Limited
• AbbVie Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Allergan Plc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Hospital Infection Therapeutics market

• Drug Class
  • Antibacterial Drugs
    • Cell Wall Synthesis Inhibitors
    • Protein Synthesis Inhibitors
    • Others
  • Antiviral Drugs
  • Antifungal Drugs
• Infection Type
  • Urinary Tract Infections
  • Ventilator-associated Pneumonia
  • Surgical Site Infections
  • Bloodstream Infections
  • Other Hospital Infections

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Hospital Infection Therapeutics industry analysis from 2022 to 2030 to identify the prevailing Hospital Infection Therapeutics industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Hospital Infection Therapeutics industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Hospital Infection Therapeutics industry trends, key players, market segments, application areas, and market growth strategies.

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7139

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/